Molecular Partners Reports Nine Active Trial Sites And Ongoing Treatment In Phase 2 MP0317 Cholangiocarcinoma Study, With Data Update Expected In 2027 And Completion In 2028

Molecular Partners Q2 EPS $(0.89) Misses $(0.45) Estimate

Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.45) by 95.56 percent. This is a 31.34 percent decrease over losses of $(0.67) per share

Molecular Partners Reports H1 2026 Financial Results With Net Loss Narrowing To CHF 26.7M From CHF 37.2M YoY, And Cash Position Of CHF 67.9M

Molecular Partners Highlights Multispecific Radio-DARPins Formatted As Bispecific Or 2-In-1 DuoDARPin To Address Tumor Heterogeneity

Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacyPresentation outlines Radio-DARPins’ ability to match target and disease biology for